Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data

被引:57
作者
Xu, Chuanhui [1 ]
Yi, Zixi [2 ]
Cai, Ruyi [2 ]
Chen, Ru [3 ]
Thong, Bernard Yu-Hor [1 ]
Mu, Rong [2 ]
机构
[1] Tan Tock Seng Hosp, Dept Rheumatol Allergy & Immunol, Singapore 308433, Singapore
[2] Peking Univ Third Hosp, Dept Rheumatol & Immunol, 49 Huayuan North Rd, Beijing 100191, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
关键词
Rheumatic diseases; COVID-19; Outcomes; SARS-CoV-2; CORTICOSTEROIDS; ARTHRITIS; COHORT; SERIES;
D O I
10.1016/j.autrev.2021.102778
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The impact of rheumatic diseases on COVID-19 infection remains poorly investigated. Here we performed a systematic review and meta-analysis to evaluate the outcomes of COVID-19 in patients with rheumatic diseases. Methods: We systematically searched PubMed, Embase, Cochrane Library, Scopus and preprint database up to 29th August 2020, for publications with confirmed COVID-19 infection in patients with rheumatic diseases. The primary outcomes were the rates of hospitalization, oxygen support, intensive care unit (ICU) admission and death. A meta-analysis of effect sizes using the random-effects models was performed, and meta-regression analyses were performed to explore heterogeneity. The data from the COVID-19 Global Rheumatology Alliance physician registry (the COVID-19 GRA) was used as a reference. Results: A total of 31 articles involving 1138 patients were included in this systematic review and meta-analysis. The publications were from Europe, Asia and North America, but none from other continents. The overall rates of hospitalization, oxygen support, ICU admission and fatality among COVID-19 infected patients with rheumatic diseases were 0.58 (95% confidence interval (CI) 0.48-0.67), 0.33 (95% CI 0.21-0.47), 0.09 (95% CI 0.05-0.15) and 0.07 (95% CI 0.03-0.11), respectively. The rate of oxygen support in Europe (0.48, 95% CI 0.4-0.57) was higher than that in other continents. Among all hospitalized patients, the rates of oxygen support, ICU admission and fatality were 0.61 (95% CI 0.48-0.73), 0.13 (95% CI 0.07-0.21) and 0.13 (95% CI 0.09-0.18), respectively. The fatality rate was highest in Europe (0.19, 95% CI 0.15-0.24). The fatality rate was higher both in this meta-analysis and the COVID-19 GRA (7.0% and 6.7%, respectively) than that (3.4%) in WHO database, although the age, gender and comorbidity were not matched. Conclusion: Patients with rheumatic diseases remain vulnerable with substantial rates of severe outcomes and a geographic variation. More studies were urgently needed to elucidate the risk factors of severe outcomes in this population.
引用
收藏
页数:8
相关论文
共 61 条
[1]   Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis [J].
Akiyama, Shintaro ;
Hamdeh, Shadi ;
Micic, Dejan ;
Sakuraba, Atsushi .
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) :384-391
[2]  
[Anonymous], CORONAVIRUS DIS COVI
[3]  
[Anonymous], Coronavirus (COVID-19), infection in pregnancy
[4]   COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs [J].
Ansarin, Khalil ;
Taghizadieh, Ali ;
Safiri, Saeid ;
Malek Mahdavi, Aida ;
Ranjbar, Shirin ;
Teymouri, Soheil ;
Ahangari Maleki, Masoud ;
Khabbazi, Alireza .
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (10)
[5]   No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany) [J].
Aries, Peer ;
Iking-Konert, Christof .
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (12)
[6]   Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD [J].
Benucci, Maurizio ;
Damiani, Arianna ;
Giannasi, Gianfranco ;
Li Gobbi, Francesca ;
Quartuccio, Luca ;
Grossi, Valentina ;
Infantino, Maria ;
Manfredi, Mariangela .
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (02)
[7]   A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [J].
Boulware, David R. ;
Pullen, Matthew F. ;
Bangdiwala, Ananta S. ;
Pastick, Katelyn A. ;
Lofgren, Sarah M. ;
Okafor, Elizabeth C. ;
Skipper, Caleb P. ;
Nascene, Alanna A. ;
Nicol, Melanie R. ;
Abassi, Mahsa ;
Engen, Nicole W. ;
Cheng, Matthew P. ;
LaBar, Derek ;
Lother, Sylvain A. ;
MacKenzie, Lauren J. ;
Drobot, Glen ;
Marten, Nicole ;
Zarychanski, Ryan ;
Kelly, Lauren E. ;
Schwartz, Ilan S. ;
McDonald, Emily G. ;
Rajasingham, Radha ;
Lee, Todd C. ;
Hullsiek, Kathy H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) :517-525
[8]   COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine [J].
Bozzalla Cassione, Emanuele ;
Zanframundo, Giovanni ;
Biglia, Alessandro ;
Codullo, Veronica ;
Montecucco, Carlomaurizio ;
Cavagna, Lorenzo .
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) :1382-1382
[9]  
Brikman Shay, 2020, Isr Med Assoc J, V8, P439
[10]   COVID-19: immunopathology and its implications for therapy [J].
Cao, Xuetao .
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (05) :269-270